Naples

• The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended recruitment
  2024-510605-28-00 5 2018-11-27 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
• Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib Ended recruitment
  2023-505376-30-00 4 2018-10-30 BRAF V600 mutation–positive unresectable or metastatic melanoma
• Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma Ended recruitment
  2022-501966-23-00 5 2018-09-11 Resected High-Risk Stage II Melanoma
• A Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Re … Ended recruitment
  2023-506861-76-00 5 2018-08-09 Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplasti
• A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination with Chemotherapy and/or Immunotherapy in Subjects with Metastat … Ended recruitment
  2024-511649-21-00 4 2018-08-01 Advanced cancer of the stomach or the gastroesophageal junction
• Extended Access of Momelotinib for Subjects with Myelofibrosis Ended recruitment
  2023-508018-41-00 4 2018-07-27 Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
• AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended recruitment
  2023-509856-32-00 5 2018-07-15 acute lymphoblastic leukemia in children and adolescents
• A Study of Relatlimab plus Nivolumab Versus Nivolumab Alone in Participants with Advanced Melanoma Ended recruitment
  2024-510913-13-00 10 2018-05-18 Previously Untreated Metastatic or Unresectable Melanoma
• A Study of Glofitamab (RO7082859) and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patient … Ended recruitment
  2023-505222-34-00 7 2018-04-23 Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)
• A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Res … Ended recruitment
  2023-508726-10-00 5 2018-03-28 Hepatocellular Carcinoma
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended recruitment
  2024-513070-21-00 4 2018-02-15 Relapsed Acute Lymphoblastic Leukemia (ALL)
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small C … Ended recruitment
  2023-507500-31-00 10 2017-08-22 Advanced or metastatic Non-small cell lung cancer (NSCLC)
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended recruitment
  2023-509671-17-00 5 2017-07-12 Breast Cancer
• A Study to Assess Safety, Effectiveness, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Patients with Paroxys … Ended recruitment
  2023-506287-14-00 7 2017-04-21 Paroxysmal nocturnal hemoglobinuria (PNH)
• A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended recruitment
  2023-506390-35-00 1 2017-04-19 Patients with Advanced Solid Tumors
• Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospect … Ended recruitment
  2023-510434-83-00 6 2016-10-17 Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
• A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer Ended recruitment
  2023-507175-22-00 4 2016-09-19 Metastatic Breast Cancer
• A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Ended recruitment
  2024-512115-50-00 4 2016-06-22 Relapsed/Refractory DLBCL
• Neoadjuvant L19IL2/L19TNF- Pivotal study Ended recruitment
  2024-515749-40-00 5 2016-02-25 Malignant melanoma of the skin in patients with locally advanced and f
• PhII Trial of Pembrolizumab in Advanced Solid Tumors Ended recruitment
  2022-501253-37-00 4 2016-02-02 (A) Anal Squamous Cell Carcinoma, (B) Biliary Adenocarcinoma (gallblad
• BEVERLY: A randomized open-label phase 3 trial comparing bevacizumab + erlotinib vs erlotinib alone as first line treatment of patients with … Ended recruitment
  2024-516843-15-00 5 2015-11-23 Non-squamous Non-small Cell Lung Cancer
• Phase 2 open label randomized study of radiotherapy, concomitant nimotuzumab and vinorelbine and re-irradiation at relapse versus radiothera … Ended recruitment
  2024-513654-30-00 4 2015-11-04 Diffuse intrinsic pontine glioma
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m

Showing 913–936 of 1,177 trials